Literature DB >> 10367401

Seroprevalence of Helicobacter pylori infection in patients with hepatitis B.

X G Fan1, Y Y Zou, A H Wu, T G Li, G L Hu, Z Zhang.   

Abstract

Helicobacter pylori infection has been investigated extensively in immunocompromised hosts, such as those with acquired immunodeficiency syndrome (AIDS) and organ transplant recipients. However, few reports on H. pylori prevalence in individuals with chronic HBV infection are available. The aim of this serological study is to investigate H. pylori prevalence in patients with hepatitis B. Ninety-six consecutive hospitalised patients with chronic hepatitis B were studied, together with 104 age-matched healthy individuals of similar socioeconomic status and with no evidence of hepatitis B virus infection or liver diseases. Serum samples from both groups were tested for specific IgG antibodies to H. pylori, using enzyme-linked immunosorbent assay (ELISA). Of the 96 patients with hepatitis B, 55 (57.3%) were positive for serum IgG anti-H. pylori, significantly greater than in the control group of 104, where 44 (42.3%) were positive (P < 0.05). In addition, the seroprevalence of H. pylori in the 45 patients who were positive for hepatitis B envelope antigen (HBeAg) and/or HBV-DNA was 75.6% (34), compared to 41.2% (21) in the 51 patients who were negative (P < 0.005). An increase in H. pylori prevalence is present in patients with chronic hepatitis B. Further study is needed to determine whether eradication of H. pylori will benefit these patients.

Entities:  

Mesh:

Year:  1998        PMID: 10367401

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  8 in total

1.  Helicobacter infection in hepatocellular carcinoma tissue.

Authors:  Shi-Ying Xuan; Ning Li; Xin Qiang; Rong-Rong Zhou; Yong-Xin Shi; Wen-Jie Jiang
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

2.  Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma.

Authors:  Y Huang; X-G Fan; Z-M Wang; J-H Zhou; X-F Tian; N Li
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

3.  Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection.

Authors:  Chang-Hai Liu; Wei Jiang; Dong-Bo Wu; Qing-Min Zeng; You-Juan Wang; Hong Tang
Journal:  Dig Dis Sci       Date:  2022-10-13       Impact factor: 3.487

4.  Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Authors:  Maria P Dore; Giuseppe Realdi; Daniela Mura; David Y Graham; Antonia R Sepulveda
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 5.  Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases.

Authors:  Elizabeth Ma Rabelo-Gonçalves; Bruna M Roesler; José Mr Zeitune
Journal:  World J Hepatol       Date:  2015-12-28

6.  Lack of association between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis.

Authors:  Marilena Durazzo; Floriano Rosina; Alberto Premoli; Enrico Morello; Sharmila Fagoonee; Rosaria Innarella; Enrico Solerio; Rinaldo Pellicano; Mario Rizzetto
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

7.  Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method.

Authors:  Tahereh Pirouz; Leila Zounubi; Hussein Keivani; Nasser Rakhshani; Mahshid Hormazdi
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

8.  Association between Severity of Liver Disease, Frequency of Helicobacter pylori Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection.

Authors:  Amal A Mohamed; Amal A Elshimy; Abir O El Sadik; Elham Ezzat; Mona Nasar; Shereen S M Elshaer; Moataz M Sayed
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.